首页 | 本学科首页   官方微博 | 高级检索  
     


A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era
Authors:Rachel Thompson  Angela Abicht  David Beeson  Andrew G. Engel  Bruno Eymard  Emmanuel Maxime  Hanns Lochmüller
Affiliation:1.Institute of Genetic Medicine,Newcastle University,Newcastle upon Tyne,UK;2.Medical Genetics Centre,Munich,Germany;3.Nuffield Department of Clinical Neurosciences,University of Oxford,Oxford,UK;4.Department of Neurology,Mayo Clinic,Rochester,USA;5.Institut de Myologie,Paris,France;6.INSERM US14 - Orphanet, Plateforme Maladies Rares,Paris,France;7.Children’s Hospital of Eastern Ontario (CHEO) Research Institute,University of Ottawa,Ottawa,Canada;8.Department of Neuropediatrics and Muscle Disorders,Medical Center – University of Freiburg, Faculty of Medicine,Freiburg,Germany;9.Centro Nacional de Análisis Genómico (CNAG-CRG), Center for Genomic Regulation,Barcelona Institute of Science and Technology (BIST),Barcelona,Spain
Abstract:

Background

Congenital myasthenic syndromes (CMS) are a heterogeneous group of inherited neuromuscular disorders sharing the common feature of fatigable weakness due to defective neuromuscular transmission. Despite rapidly increasing knowledge about the genetic origins, specific features and potential treatments for the known CMS entities, the lack of standardized classification at the most granular level has hindered the implementation of computer-based systems for knowledge capture and reuse. Where individual clinical or genetic entities do not exist in disease coding systems, they are often invisible in clinical records and inadequately annotated in information systems, and features that apply to one disease but not another cannot be adequately differentiated.

Results

We created a detailed classification of all CMS disease entities suitable for use in clinical and genetic databases and decision support systems. To avoid conflict with existing coding systems as well as with expert-defined group-level classifications, we developed a collaboration with the Orphanet nomenclature for rare diseases, creating a clinically understandable name for each entity and placing it within a logical hierarchy that paves the way towards computer-aided clinical systems and improved knowledge bases for CMS that can adequately differentiate between types and ascribe relevant expert knowledge to each.

Conclusions

We suggest that data science approaches can be used effectively in the clinical domain in a way that does not disrupt preexisting expert classification and that enhances the utility of existing coding systems. Our classification provides a comprehensive view of the individual CMS entities in a manner that supports differential diagnosis and understanding of the range and heterogeneity of the disease but that also enables robust computational coding and hierarchy for machine-readability. It can be extended as required in the light of future scientific advances, but already provides the starting point for the creation of FAIR (Findable, Accessible, Interoperable and Reusable) knowledge bases of data on the congenital myasthenic syndromes.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号